Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Monte Rosa Therapeutics (NASDAQ:GLUE)

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Monte Rosa Therapeutics (NASDAQ:GLUE)

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 …

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of […] The post Monte Rosa Therapeutics Announces Pricing of $300 Million Underw…

Biotech Monte Rosa is selling $300M in new shares to investors

Monte Rosa prices 11.1M shares at $24 plus 1.4M pre-funded warrants, targeting $300M in gross proceeds; deal expected to close by Jan. 12.